Summary
Neoadjuvant chemotherapy consisting of 2–3 courses of cisplatin, vincristine, and bleomycin was used in the primary treatment of 36 consecutive patients with locally advanced early-stage cervical carcinoma [International Federation of Gynecology and Obstetrics (GIGO) stages I b or IIa; tumor size, ≥4 cm]. The effectiveness of the preoperative chemotherapy was evaluated in the surgical specimens. Among the 33 evaluable patients, the overall clinical response rate was 84.8%, which included a complete response in 8 patients (24.2%) and a partial response in 20 subjects (60.6%). No residual tumor was found in the surgical speciments obtained from 2 complete responders. This therapy induced varying degrees of tumor shrinkage and rendered radical surgery feasible in all evaluable cases despite the initial bulky size of the lesions. No significant difference was observed in the response rate according to age and disease stage. Lymph-node metastases were found after chemotherapy in 18.2% (6/33) of the patients. Grade II and III hematological toxicities occurred in 23.3% of the 90 chemotherapy cycles completed. Nausea and vomiting occurred to a mild to moderate degree in 75 (83.3%) cycles. These preliminary results suggest that the administration of induction chemotherapy involving two to three courses of cisplatin, vincristine, and bleomycin prior to surgery is effective in reducing the tumor volume and in providing better circumstances for surgical removal of the early yet bulky cervical tumors and results in tolerable toxicity. This protocol is now undergoing prospective randomized trials to test its impact on long-term survival.
Similar content being viewed by others
References
Burghardt E, Pickel H (1978) Local spread and lymph node involvement in cervical cancer. Obstet Gynecol 52: 138–145
Carlson JA Jr (1990) Chemotherapy of cervical cancer. Clin Obstet Gynecol 33: 910–916
Chung CK, Nahhas WA, Stryker SL, Abt AB, Mortel R (1980) Analysis of factors contributing to treatment failures in stage I B and II A carcinoma of the cervix. Am J Obstet Gynecol 138: 550–556
Dottino PR, Plaxe SC, Beddoe AM, Johnston C, Cohen CJ (1991) Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol 40: 7–11
Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson M, Houghton R, Solomon J, Green D, Russell P, Hudson CN, Langlands AO, Tattersall MHN (1983) Cervical carcinoma: a drugresponsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol 16: 275–281
Friedlander ML, Atkinson K, Coppleson JVM, Elliot P, Green D, Houghton R, Solomon HJ, Russell P, Tattersall MHN (1984) The integration of chemotherapy into the management of locally advanced cervical cancer: a pilot study. Gynecol Oncol 19: 1–7
Fuller AF, Elliott, N, Kosloff C, Hoskins W, Lewis JL (1989) Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 33: 34–39
Kim DS, Moon H, Kang KJ (1985) Primary chemotherapy and postoperative adjuvant chemotherapy in the treatment of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 22: 59–64
Kim DS, Moon H, Hwang YY, Cho SH (1988) preoperative adjuvant chemotherapy in the treatment of cervical cancer stage Ib, IIa, and IIb with bulky tumor. Gynecol Oncol 29: 321–332
Kim DS, Moon H, Kim KT, Hwang YY, Cho SH, Kim SR (1989) Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor. Gynecol Oncol 33: 225–230
Morgan LS, Nelson JH (1982) Surgical treatment of early cervical cancer. Semin Oncol 9: 312–329
Panici PB, Greggi S, Scambia G, Salerno M, Mancuso S (1988) Complete response to pre-operative chemotherapy in stage IIIB cervical carcinoma. Case report. Br J Obstet Gynecol 95: 946–948
Panici PB, Scambia G, Greggi S, Roberto PD, Baiocchi G Mancuso S (1988) Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstet Gynecol 71: 344–348
Panici PB, Scambia G, Baiocchi G, Greggi S, Ragusa G, Gallo A, Conte M, Battaglia F, Laurelli G, Rabitti C, Capelli A, Mancuso S (1991) Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Cancer 67: 372–379
Park TK, Choi DH, Kim SN, Lee CH, Kim YT, Kim GE, Suh CO, Loh JK (1991) Role of induction chemotherapy in invasive cervical cancer. Gynecol Oncol 41: 107–112
Sardi JE, Paola GR di, Cachau A, Ortiz OC, Sananes C, Giaroli A, Martins D, Peluffo M (1986) A possible new trend in the management of carcinoma of the cervix uteri. Gynecol Oncol 25: 139–149
Sardi JE, Paola GR di, Giaroli A, Sananes C, Rueda NG, Cachau A, Vighi S, Burlando S (1988) Results of a phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri. Gynecol Oncol 31: 256–261
Tobias J, Buxton EJ, Blackledge G, Mould JJ, Monaghan J, Spooner D, Chetiyawardana A (1990) Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemother Pharmacol 26 [Suppl]: 63–65
Weiner SA, Aristizabal S, Alberts DS, Surwit EA, Deatherage-Deuser K (1988) A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. Gynecol Oncol 30: 1–6
White CD, Morley GW, Kumar NB (1984) The prognostic significance of tumor emboli in lymphatic or vascular spaces of the cervical stroma in stage IB squamous cell carcinoma of the cervix. Am J Obstet Gynecol 149: 342–349
World Health Organization (1979) Handbook for reporting results of cancer treatment. Offset publication 48. WHO, Geneva, pp 16–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chang, HC., Lai, CH., Chou, P.C. et al. Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma. Cancer Chemother. Pharmacol. 30, 281–285 (1992). https://doi.org/10.1007/BF00686296
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686296